Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 333 restricted stock units (RSUs) to one newly-hired employee as of July 31, 2025. The RSUs will vest over three years, with 33 1/3% vesting annually on the grant date anniversary.
The grant was made under the company's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato 333 unit脿 azionarie vincolate (RSU) a un nuovo dipendente assunto al 31 luglio 2025. Le RSU matureranno in tre anni, con un 33 1/3% che matura ogni anno nell'anniversario della data di assegnazione.
L'assegnazione 猫 stata effettuata nell'ambito del Piano di Incentivazione Azionaria 2022 dell'azienda e rispetta la Regola di Quotazione Nasdaq 5635(c)(4). Le RSU prevedono clausole di maturazione accelerata in caso di evento di cambio di controllo seguito da un licenziamento qualificato.
Karyopharm Therapeutics (Nasdaq: KPTI), una empresa farmac茅utica en etapa comercial enfocada en terapias contra el c谩ncer, ha otorgado 333 unidades restringidas de acciones (RSUs) a un empleado reci茅n contratado al 31 de julio de 2025. Las RSUs se consolidar谩n durante tres a帽os, con un 33 1/3% consolid谩ndose anualmente en el aniversario de la fecha de concesi贸n.
La concesi贸n se realiz贸 bajo el Plan de Incentivos de Acciones de Inducci贸n 2022 de la compa帽铆a y cumple con la Regla de Listado Nasdaq 5635(c)(4). Las RSUs incluyen disposiciones de consolidaci贸n acelerada en caso de un evento de cambio de control seguido por una terminaci贸n laboral calificada.
Karyopharm Therapeutics (Nasdaq: KPTI)電� 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 靸侅梾 雼硠 鞝滌暯 須岇偓搿�, 2025雲� 7鞗� 31鞚� 旮办鞙茧 鞁犾瀰 歆侅洂 頃� 氇呾棎瓴� 333臧滌潣 鞝滍暅 欤检嫕 雼渼(RSUs)毳� 攵�鞐枅鞀惦媹雼�. RSU電� 3雲勳棎 瓯胳硱 鞝愳鞝侅溂搿� 旆摑霅橂┌, 毵る厔 攵�鞐澕 旮半厫鞚检棎 33 1/3%鞌� 旆摑霅╇媹雼�.
鞚� 攵�鞐姅 須岇偓鞚� 2022雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, Nasdaq 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅暕雼堧嫟. RSU鞐愲姅 歆�氚瓣秾 氤�瓴� 靷贝 氚滌儩 頉� 鞝侁博 瓿犾毄 膦呺 鞁� 臧�靻� 旆摑 臁绊暛鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Karyopharm Therapeutics (Nasdaq : KPTI), une soci茅t茅 pharmaceutique en phase commerciale sp茅cialis茅e dans les th茅rapies contre le cancer, a attribu茅 333 unit茅s d'actions restreintes (RSU) 脿 un nouvel employ茅 embauch茅 au 31 juillet 2025. Les RSU seront acquises sur une p茅riode de trois ans, avec 33 1/3 % acquises chaque ann茅e 脿 la date anniversaire de l'attribution.
Cette attribution a 茅t茅 r茅alis茅e dans le cadre du Plan d'Incitation en Actions d'Induction 2022 de la soci茅t茅 et est conforme 脿 la r猫gle de cotation Nasdaq 5635(c)(4). Les RSU comprennent des dispositions d'acquisition acc茅l茅r茅e en cas de changement de contr么le suivi d'une cessation d'emploi qualifi茅e.
Karyopharm Therapeutics (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf Krebstherapien, hat zum 31. Juli 2025 333 Restricted Stock Units (RSUs) an einen neu eingestellten Mitarbeiter vergeben. Die RSUs werden 眉ber drei Jahre ausgegeben, wobei 33 1/3 % j盲hrlich am Jahrestag des Gew盲hrungsdatums freigegeben werden.
Die Zuteilung erfolgte im Rahmen des Inducement Stock Incentive Plans 2022 des Unternehmens und entspricht der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs enthalten eine beschleunigte Freigaberegelung im Falle eines Kontrollwechsels gefolgt von einer qualifizierten Beendigung des Arbeitsverh盲ltnisses.
- None.
- None.
The RSU award will vest over three years, with 33 1/
In addition, the RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export聽dysregulation, a fundamental mechanism of oncogenesis.聽Karyopharm's lead compound and first颅in颅class, oral exportin 1 (XPO1) inhibitor, XPOVIO庐 (selinexor), is approved in the
XPOVIO庐 and NEXPOVIO庐 are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:
SOURCE Karyopharm Therapeutics Inc.
FAQ
What type of stock compensation did Karyopharm Therapeutics (KPTI) grant to its new employee?
What is the vesting schedule for Karyopharm's (KPTI) newly granted RSUs?
Under what circumstances can Karyopharm's (KPTI) RSUs vest immediately?
What regulatory rule does Karyopharm's (KPTI) RSU grant comply with?
